In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Exiqon Diagnostics

Latest From Exiqon Diagnostics

Earnings Winners & Losers: QGEN, WMGI, ALR, SN, and LIVN

Diagnostics, orthopedics, and cardiovascular device companies are among those that wait until November to report their results for the quarter that ended at the end of September. Medtech Insight’s Earnings Winners & Losers highlights some of the companies that had news to celebrate, and a few that were disappointed with the quarter.

Sales & Earnings Companies

Deals Shaping the Medical Industry (11/2008)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions Database, providing comprehensive transaction coverage from 1991 to the present.

Rational Therapeutics

Diagnostics & Drug Development; Cancer. Rational Therapeutics' ex vivo apoptotic assay,which measures cell death in culture, will help select appropriate drugs for individual cancer patients and aid in the cancer drug discovery process. The assay measures the ability of drugs, radiation, biological agents and combinations of all of the above, to induce cell death.

BioPharmaceutical Medical Device

Looking for the Next "PSA"

Cancer diagnostics has been a tough field for companies. But the need for good tests remains, and with new technologies being discovered, the opportunities still seem worth pursuing. Witness the deals signed in the field in the past half year. While none are large, they address either diagnostic companies' search for growth and high value, proprietary tests, or biotech companies' desire to foster basic research for pharmaceutical products or evaluate therapeutic impact on specific patients.

Medical Device Platform Technologies
See All

Company Information

  • Industry
  • Laboratory Testing Services
    • Anatomical Pathology
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Other Names / Subsidiaries
    • Oncotech Inc.